7.5mg Mounjaro to Wegovy: Complete Comparison Guide
7.5mg Mounjaro to Wegovy: Understanding the Key Mechanism Differences
When considering switching from 7.5mg Mounjaro to Wegovy, the fundamental difference lies in how these prescription-only medicines work within your body. Wegovy contains semaglutide, which specifically targets GLP-1 receptors to mimic your body's natural fullness hormone, helping reduce appetite and promote satiety after smaller meals. Mounjaro, by contrast, uses tirzepatide - a dual-action medication that targets both GIP and GLP-1 receptors simultaneously, potentially offering a different approach to appetite regulation and glucose metabolism.
The 7.5mg Mounjaro dose represents the second-highest maintenance level in the Mounjaro escalation schedule, whilst Wegovy's maximum dose is 2.4mg (with 7.2mg recently approved by MHRA but not yet available). These dosing differences reflect distinct molecular structures rather than relative strength - you cannot directly convert 7.5mg Mounjaro to an "equivalent" Wegovy dose, as the medications work through different pathways and have unique pharmacokinetic profiles that require individual clinical assessment.
Pricing Comparison: 7.5mg Mounjaro to Wegovy Cost Analysis
EverydayMeds offers transparent pricing for both medications, allowing you to compare costs when considering switching from 7.5mg Mounjaro to Wegovy. Wegovy pricing follows a dose-escalation schedule: £79.99 for 0.25mg starter dose, £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices.
For convenient supply continuity, our bundle options include the Intro Trio (0.25mg, 0.5mg, 1mg) at £299.99 and Ultimate Stability Trio (three 2.4mg maintenance pens) at £649.99. When comparing 7.5mg Mounjaro to Wegovy transition costs, consider that Wegovy requires a mandatory four-month dose escalation period before reaching maintenance therapy, whilst switching from Mounjaro may require clinical assessment to determine the appropriate Wegovy starting dose based on your individual response and tolerability.
Clinical Evidence: Wegovy vs Mounjaro Trial Data
Clinical trials demonstrate both medications' efficacy in weight management when used alongside reduced-calorie diet and increased physical activity. The pivotal STEP trials for Wegovy showed patients achieved approximately 15% average weight loss at 68 weeks in STEP 1, with sustained results of 15.2% at two years in STEP 5 (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial additionally demonstrated a 20% reduction in major cardiovascular events.
Mounjaro's SURMOUNT trials revealed different efficacy profiles due to its dual GIP+GLP-1 mechanism, though direct comparison between trial results isn't clinically meaningful due to different study populations, endpoints, and methodologies. Both medications require clinical assessment to determine suitability, and individual responses can vary significantly regardless of trial averages.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy's semaglutide acts as a GLP-1 receptor agonist, mimicking the incretin hormone naturally produced in your intestines when you eat. This mechanism helps slow gastric emptying, meaning food stays in your stomach longer and promotes earlier satiety signals to your brain's appetite control centres. The medication may also reduce food cravings and the psychological drive to eat by modulating reward pathways in the hypothalamus. Unlike rapid-acting appetite suppressants, Wegovy provides sustained appetite regulation throughout the week with once-weekly dosing. This mechanism specifically targets the GLP-1 pathway, offering a different therapeutic approach compared to Mounjaro's dual-receptor targeting when considering a switch from 7.5mg Mounjaro to Wegovy.
Ordering Process: From 7.5mg Mounjaro to Wegovy Assessment
Switching from 7.5mg Mounjaro to Wegovy requires a new clinical assessment through EverydayMeds' regulated process, as these are distinct prescription-only medicines with different safety profiles and contraindications. Our three-minute online assessment covers your medical history, current medications, weight management goals, and any experiences with your previous Mounjaro treatment. Our UK-registered prescribers (GPhC #9012878) review your assessment within three working days (or 24 hours with express service) to determine Wegovy suitability and appropriate starting dose. Once approved, your Wegovy prescription is dispensed from our regulated UK pharmacy and delivered next-day via temperature-controlled cold-chain logistics. This thorough process ensures safe transition between medications and appropriate clinical oversight.
Storage and Practical Considerations: Wegovy vs Mounjaro
Wegovy offers significant storage advantages when comparing to Mounjaro, particularly important for travel and daily convenience. Whilst both medications require refrigeration at 2-8°C before first use, Wegovy remains stable for up to six weeks at room temperature (below 30°C) once removed from the fridge. Mounjaro, by comparison, maintains stability for only 21 days at room temperature, making Wegovy more practical for extended travel or flexible storage needs. The Wegovy FlexTouch pen design provides clear dose indication and user-friendly injection mechanism, with once-weekly dosing typically scheduled on the same day each week. When transitioning from 7.5mg Mounjaro to Wegovy, you'll need to adjust from Mounjaro's dosing schedule to Wegovy's distinct escalation protocol starting at 0.25mg.
Transition Strategy: Moving from 7.5mg Mounjaro to Wegovy Safely
The transition from 7.5mg Mounjaro to Wegovy requires careful clinical planning, as these medications cannot be directly substituted or dose-converted due to their different mechanisms and pharmacokinetics. Most prescribers recommend allowing a washout period between medications to assess baseline appetite and weight changes, though the specific timing depends on individual factors including how long you've been on Mounjaro and your response pattern. Wegovy always starts at 0.25mg regardless of your previous Mounjaro dose, as the GLP-1-only mechanism requires its own tolerance-building schedule.
Your prescriber may suggest monitoring specific markers during the transition, including gastrointestinal tolerance, appetite changes, and weight stability between medications. Some patients find the switch from 7.5mg Mounjaro to Wegovy involves different side effect profiles or appetite regulation patterns, reflecting the distinct receptor targeting approaches. EverydayMeds' clinical team coordinates with your prescriber to ensure smooth medication transitions and appropriate follow-up scheduling.
Complete Your 7.5mg Mounjaro to Wegovy Assessment Today
Ready to explore switching from 7.5mg Mounjaro to Wegovy with expert clinical support? Start your assessment at EverydayMeds using discount code FIRST40 for new customers or DOSE25 for returning patients - these codes are applied at checkout to reach our competitive pricing starting from £79.99. Our GPhC-registered pharmacy provides both medications, allowing seamless transitions with comprehensive clinical oversight and next-day delivery. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discover whether Wegovy's GLP-1 mechanism aligns with your weight management goals. Our expert team ensures you receive appropriate clinical guidance for safe, effective medication transitions. Both Wegovy and Mounjaro remain available through our regulated UK pharmacy, giving you flexibility in your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
